Berberine and Cinnamon in Management of Diabetes

NCT ID: NCT05570357

Last Updated: 2024-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-01

Study Completion Date

2023-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this randomized clinical trial, patients with diabetes will be randomly assigned to receive either Berberine, and Cinnamon supplements or placebo for 12 weeks. Then the glycemic characteristics will be compared in two groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Group Type ACTIVE_COMPARATOR

Berberine+Cinnamon (TDS)

Intervention Type DIETARY_SUPPLEMENT

The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract

Placebo

Group Type PLACEBO_COMPARATOR

Placebo (TDS)

Intervention Type OTHER

Placebo contains Maltodexterin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Berberine+Cinnamon (TDS)

The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract

Intervention Type DIETARY_SUPPLEMENT

Placebo (TDS)

Placebo contains Maltodexterin

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 30-70 years
* Diagnosed type-2 diabetes mellitus (based on American Diabetes Association criteria)

Exclusion Criteria

* Patients with an allergy to berberine /cinamon

* Lactation, pregnancy
* Patients with any malignancy
* Patients with unrelated chronic illness
* Patients with cardiac, liver or respiratory failure
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Nutrition and Food Technology Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Azita Hekmatdoost

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Azita Hekmatdoost

Tehran, Middle East, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

996401

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Antioxidant Treatment of Type 2 Diabetes
NCT00609102 COMPLETED EARLY_PHASE1